Chemosaturation for primary and secondary liver malignancies: a comprehensive update of current evidence

Since the early 1960s, [1 –2] the technique of isolated hepatic perfusion to deliver high dose chemotherapy has raised clinical interest, but failed to gain widespread application due to overall limited clinical efficacy, significant systemic toxicity and lack of overall safety (CITATION JAMA; NEJM). [3] In 2011, however, the Hepatic CHEMOSAT Delivery System (Delcath Systems Inc., New York, NY, USA), was launched as a minimally invasive approach that facilitates percutaneous hepatic perfusion (PHP) to deliver highly concentrated chemotherapy directly to the liver, thereby “saturating” the entire organ (“chemosa turation” (CS)).
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research